Cargando…

MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?

Qualitative differences in the MHC class II antigen processing and presentation pathway may be instrumental in shaping the CD4+ T cell response directed against tumour cells. Efficient loading of many MHC class II alleles with peptides requires the assistance of H2-M, a heterodimeric MHC class II-li...

Descripción completa

Detalles Bibliográficos
Autores principales: Walter, W, Lingnau, K, Schmitt, E, Loos, M, Maeurer, M J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363595/
https://www.ncbi.nlm.nih.gov/pubmed/11027433
http://dx.doi.org/10.1054/bjoc.2000.1415
_version_ 1782153743961161728
author Walter, W
Lingnau, K
Schmitt, E
Loos, M
Maeurer, M J
author_facet Walter, W
Lingnau, K
Schmitt, E
Loos, M
Maeurer, M J
author_sort Walter, W
collection PubMed
description Qualitative differences in the MHC class II antigen processing and presentation pathway may be instrumental in shaping the CD4+ T cell response directed against tumour cells. Efficient loading of many MHC class II alleles with peptides requires the assistance of H2-M, a heterodimeric MHC class II-like molecule. In contrast to the HLA-DM region in humans, the β-chain locus is duplicated in mouse, with the H2-Mb1 (Mb1β-chain distal to H2-Mb2 (Mb2) and the H2-Ma (Ma) α-chain gene). Here, we show that murine MHC class II and H2-M genes are coordinately regulated in murine tumour cell lines by T helper cell 1 (IFN-γ) and T helper cell 2 (IL-4 or IL-10) cytokines in the presence of the MHC class II-specific transactivator CIITA as determined by mRNA expression and Western blot analysis. Furthermore, Mαβ1 and Mαβ2 heterodimers are differentially expressed in murine tumour cell lines of different histology. Both H2-M isoforms promote equally processing and presentation of native protein antigens to H2-A(d)- and H2-E(d)-restricted CD4+ T cells. Murine tumour cell lines could be divided into three groups: constitutive MHC class II and CIITA expression; inducible MHC class II and CIITA expression upon IFN-γ-treatment; and lack of constitutive and IFN-γ-inducible MHC class II and CIITA expression. These differences may impact on CD4+ T cell recognition of cancer cells in murine tumour models. © 2000 Cancer Research Campaign
format Text
id pubmed-2363595
institution National Center for Biotechnology Information
language English
publishDate 2000
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23635952009-09-10 MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? Walter, W Lingnau, K Schmitt, E Loos, M Maeurer, M J Br J Cancer Regular Article Qualitative differences in the MHC class II antigen processing and presentation pathway may be instrumental in shaping the CD4+ T cell response directed against tumour cells. Efficient loading of many MHC class II alleles with peptides requires the assistance of H2-M, a heterodimeric MHC class II-like molecule. In contrast to the HLA-DM region in humans, the β-chain locus is duplicated in mouse, with the H2-Mb1 (Mb1β-chain distal to H2-Mb2 (Mb2) and the H2-Ma (Ma) α-chain gene). Here, we show that murine MHC class II and H2-M genes are coordinately regulated in murine tumour cell lines by T helper cell 1 (IFN-γ) and T helper cell 2 (IL-4 or IL-10) cytokines in the presence of the MHC class II-specific transactivator CIITA as determined by mRNA expression and Western blot analysis. Furthermore, Mαβ1 and Mαβ2 heterodimers are differentially expressed in murine tumour cell lines of different histology. Both H2-M isoforms promote equally processing and presentation of native protein antigens to H2-A(d)- and H2-E(d)-restricted CD4+ T cells. Murine tumour cell lines could be divided into three groups: constitutive MHC class II and CIITA expression; inducible MHC class II and CIITA expression upon IFN-γ-treatment; and lack of constitutive and IFN-γ-inducible MHC class II and CIITA expression. These differences may impact on CD4+ T cell recognition of cancer cells in murine tumour models. © 2000 Cancer Research Campaign Nature Publishing Group 2000-11 /pmc/articles/PMC2363595/ /pubmed/11027433 http://dx.doi.org/10.1054/bjoc.2000.1415 Text en Copyright © 2000 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Walter, W
Lingnau, K
Schmitt, E
Loos, M
Maeurer, M J
MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
title MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
title_full MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
title_fullStr MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
title_full_unstemmed MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
title_short MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
title_sort mhc class ii antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363595/
https://www.ncbi.nlm.nih.gov/pubmed/11027433
http://dx.doi.org/10.1054/bjoc.2000.1415
work_keys_str_mv AT walterw mhcclassiiantigenpresentationpathwayinmurinetumourstumourevasionfromimmunosurveillance
AT lingnauk mhcclassiiantigenpresentationpathwayinmurinetumourstumourevasionfromimmunosurveillance
AT schmitte mhcclassiiantigenpresentationpathwayinmurinetumourstumourevasionfromimmunosurveillance
AT loosm mhcclassiiantigenpresentationpathwayinmurinetumourstumourevasionfromimmunosurveillance
AT maeurermj mhcclassiiantigenpresentationpathwayinmurinetumourstumourevasionfromimmunosurveillance